Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 2/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.35 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.34 |
| ▸ | TP53 | P04637 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4750497 | 0.78 | SMN1; SMN2 (0.38) | MAPTRAB9AGAAHTTL3MBTL1 | |
| SCHEMBL27779595 | 0.73 | NPC1 (0.33) | MAPTRAB9AL3MBTL1NPC1 | |
| SCHEMBL6973163 | 0.73 | NPC1 (0.44) | MAPTRAB9AGAAHTTL3MBTL1 | |
| SCHEMBL10505563 | 0.71 | KDM4E (0.56) | RAB9AALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL9597126 | 0.70 | NPC1 (0.35) | MAPTHTTL3MBTL1ALDH1A1KDM4E | |
| SCHEMBL9587476 | 0.70 | KDM4E (0.41) | MAPTRAB9AGAAGFERL3MBTL1 | |
| SCHEMBL3289198 | 0.69 | SMN1; SMN2 (0.43) | PI4KAPI4KBPIK3CAMAPTRAB9A | |
| SCHEMBL5969760 | 0.68 | DYRK1A (0.59) | PIK3CARAB9AHTTPIK3CGSMN1; SMN2 | |
| SCHEMBL29392710 | 0.67 | PI4KA (0.58) | PI4KAPI4KBPIK3CAMAPTRAB9A | |
| SCHEMBL75245 | 0.67 | PI4KA (0.58) | PI4KAPI4KBPIK3CAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076602-A | Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses | 嘉兴优博生物技术有限公司 | 2024-05-24 | — | — | CN | claimed |
| US-20240101546-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | EUBULUS BIOTHERAPEUTICS INC (CN) | 2024-03-28 | — | — | US | claimed |
| EP-3558969-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | Janssen Pharmaceutica NV (BE) | 2019-10-30 | — | — | EP | claimed |
| WO-2018119036-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN BIOTECH, INC. (US) | 2018-06-28 | — | — | WO | claimed |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN-CILAG (FR) | 2018-06-21 | — | — | US | claimed |
| US-20060128634-A1 | Alpha, alpha-disubstituted benzylglycine derivatives as HIV protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-06-15 | — | — | US | claimed |
| US-6943170-B2 | N-cycloalkylglycines as HIV protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-13 | — | — | US | claimed |
| US-20040142878-A1 | N-cycloalkylglycines as HIV protease inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-07-22 | — | — | US | claimed |
| WO-2004043911-A2 | N-CYCLOALKYLGLYCINES AS HIV PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | claimed |
| WO-2004043355-A2 | ALPHA, ALPHA-DISUBSTITUTED BENZYLGLYCINE DERIVATIVES AS HIV PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | claimed |
| CN-113473971-B | Pharmaceutical formulations | 詹森药业有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-118076602-A | Heteroaryl-acetylenes, pharmaceutical compositions thereof and their therapeutic uses | 嘉兴优博生物技术有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240101546-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | EUBULUS BIOTHERAPEUTICS INC (CN) | 2024-03-28 | — | — | US | disclosed |
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-05 | — | — | US | disclosed |
| CN-115884773-A | Pharmaceutical preparation | 詹森药业有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-0815124-A1 | HETEROCYCLECARBONYL AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-01-07 | — | — | EP | disclosed |
| WO-1996028465-A1 | HETEROCYCLECARBONYL AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-19 | — | — | WO | disclosed |
| EP-0347766-B1 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | THOMAE GMBH DR K (DE) | 1994-05-25 | — | — | EP | disclosed |
| US-5068325-A | Dopaminergic systems as hypotensives, sedatives, antitussives and/or antiphlogistics | KARL THOMAE GMBH (DE) | 1991-11-26 | — | — | US | disclosed |
| EP-0347766-A2 | 4,5,7,8-Tetrahydro-6H-thiazolo[5,4-d]azepines, their preparation and their use as medicaments | Dr. Karl Thomae GmbH (DE) | 1989-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101546-A1 | HETEROARYL-ACETYLENES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | GPX4, GPX1, ACAT1 | PI4KA 3370/4885PI4KB 3020/4885PIK3CA 4385/4885 |
| US-20060128634-A1 | Alpha, alpha-disubstituted benzylglycine derivatives as HIV protease inhibitors | PEPD, DNPEP, PREP | PI4KA 2600/4885PI4KB 3523/4885PIK3CA 2697/4885 |
| US-20230310413-A1 | PHARMACEUTICAL FORMULATIONS COMPRISING A MALT1 INHIBITOR AND A MIXTURE OF POLYETHYLENE GLYCOL WITH A FATTY ACID | MALT1, MGAM, MGLL | PI4KA 1557/4885PI4KB 1720/4885PIK3CA 486/4885 |
| US-20040142878-A1 | N-cycloalkylglycines as HIV protease inhibitors | DNPEP, ANPEP, PREP | PI4KA 1981/4885PI4KB 3583/4885PIK3CA 1942/4885 |
| US-20180170909-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | MALT1, PPP3R1, SQSTM1 | PI4KA 1711/4885PI4KB 1340/4885PIK3CA 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.